<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5250">
  <stage>Registered</stage>
  <submitdate>7/09/2015</submitdate>
  <approvaldate>7/09/2015</approvaldate>
  <nctid>NCT02557217</nctid>
  <trial_identification>
    <studytitle>NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction</studytitle>
    <scientifictitle>A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults Who Have Left Ventricular Systolic Dysfunction Following Myocardial Infarction</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ACTRN12615000609550</secondaryid>
    <secondaryid>NP202-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>ST Elevation Myocardial Infarction</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - NP202
Other interventions - Placebo

Experimental: NP202 - 1000mg oral NP202 daily for 90 days

Placebo Comparator: Placebo - Oral placebo daily for 90 days


Treatment: drugs: NP202
Active

Other interventions: Placebo
Placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy as measured by Change from baseline in left ventricular end systolic volume index (LVESVi) - Change from baseline in left ventricular end systolic volume index (LVESVi) as assessed by MRI at 3 months</outcome>
      <timepoint>From baseline to 3 months post MI</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by Change from baseline in LV end diastolic volume index (LVEDVi) - Change from baseline in LV end diastolic volume index (LVEDVi) as assessed by MRI at 3 months.</outcome>
      <timepoint>From baseline to 3 months post MI</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by Change from baseline in LV ejection fraction (LVEF) - Change from baseline in LVEF as assessed by MRI at 3 months.</outcome>
      <timepoint>From baseline to 3 months post MI</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by Change from baseline in LV diastolic function - Changes from baseline in LV diastolic function based on LV peak filling rate as assessed by MRI at 3 months.</outcome>
      <timepoint>From baseline to 3 months post MI</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy as measured by Change from baseline in relative infarct size - Change from baseline in relative infarct size as a percent of LV mass as assessed by late contrast enhancement MRI at 3 months.</outcome>
      <timepoint>From baseline to 3 months post MI</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have had a confirmed ST elevation myocardial infarction (STEMI) in the previous 5
             days, which met all of the following criteria;

               -  = 0.2mV ST elevation in 2 or more V1 - V6 leads with presentation in a maximum of
                  12 hours of onset of symptoms

               -  Troponin levels &gt;10 x upper limit of normal (ULN) at the site's local laboratory.

               -  Successful revascularisation by Percutaneous Coronary Intervention (PCI)

          -  Have left ventricular dysfunction post STEMI as evidenced by left ventricular ejection
             fraction (LVEF) =40% confirmed by echocardiogram at screening.

          -  Are receiving guideline-directed medical therapy for acute MI and post-MI left
             ventricular (LV) dysfunction according to national cardiology society/heart
             association STEMI guidelines.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known cardiomyopathy or heart failure prior to MI.

          -  Cardiogenic shock and/or systolic blood pressure &lt;85mmHg at Screening.

          -  Clinical history of ejection fraction =40% prior to this MI, or multiple prior MIs.

          -  Daily use of non-steroidal anti-inflammatory drugs (NSAIDs) and/or cyclooxygenase-2
             (COX-2) inhibitors in the past month.

          -  Presence of device/hardware incompatible with MRI

          -  Estimated glomerular filtration rate (eGFR) &lt;30ml/min

          -  Liver function tests 3 x ULN due to non-cardiac disease

          -  Have received any investigational research agent within 30 days or 5 half-lives
             (whichever is longer) prior to the first dose of investigational product.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>John Hunter Hospital - Newcastle</hospital>
    <postcode>2305 - Newcastle</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Armaron Bio Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>NP202 is an experimental drug being developed by Armaron Bio Pty Ltd for potential use as a
      treatment for people after they have had a heart attack (MI).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02557217</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Grant McLachlan</name>
      <address>Sponsor GmbH</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Grant McLachlan</name>
      <address />
      <phone>+61 3 9652 2117</phone>
      <fax />
      <email>grant.mclachlan@armaronbio.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>